{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:31:50Z","timestamp":1777858310299,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Psychopharmacol"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Cochrane recently published a review of esketamine and other glutamate receptor modulators in depression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>To address the limitations of the review, analyses of esketamine data were conducted to provide additional perspective to the reviewers\u2019 interpretation of their findings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Response rate, remission rate, and change from baseline in Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score were determined using data from\n                      <jats:italic toggle=\"yes\">all<\/jats:italic>\n                      esketamine phase 2\/3 registration studies of treatment-resistant depression (TRD) and, separately,\n                      <jats:italic toggle=\"yes\">all<\/jats:italic>\n                      esketamine phase 2\/3 registration studies of major depressive disorder (MDD) and active suicidal ideation with intent. Outcomes were assessed at all timepoints (i.e., 24\u2009h, 72\u2009h (MDD with active suicidal intent only), and 1, 2, and 4\u2009weeks). Enrollment criteria of the TRD studies were different than those of the studies of MDD and active suicidal ideation with intent, resulting in differences in patients\u2019 clinical characteristics and depression severity between the cohorts. Thus, we did not compare results between these cohorts (as was done in the Cochrane review).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\/outcomes:<\/jats:title>\n                    <jats:p>In the combined TRD studies, a statistically significant between-group difference favored esketamine plus antidepressant over antidepressant plus placebo at 24\u2009h (based on response, remission, and change in MADRS score), 1\u2009week (change in MADRS score), 2\u2009weeks (response and change in MADRS score), and 4\u2009weeks (response, remission, and change in MADRS score). In the combined studies of MDD and active suicidal ideation with intent, the between-group difference was statistically different, favoring esketamine plus standard-of-care over placebo plus standard-of-care, at 24\u2009h (response, remission, and change in MADRS score), 72\u2009h and 1\u2009week (change in MADRS score), 2\u2009weeks (response), and 4\u2009weeks (response, remission, and change in MADRS score). For both study types, the between-group difference in outcomes was not statistically significant at the other timepoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions\/interpretation:<\/jats:title>\n                    <jats:p>Esketamine improves response, remission, and depressive symptoms as early as 24\u2009h post-first dose among patients with TRD and among patients with MDD and active suicidal ideation with intent.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/02698811221123046","type":"journal-article","created":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T08:00:39Z","timestamp":1665475239000},"page":"836-844","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Commentary on Cochrane review: \u201cKetamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder\u201d"],"prefix":"10.1177","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3312-1557","authenticated-orcid":false,"given":"Stephane","family":"Borentain","sequence":"first","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pooja","family":"Desai","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Jing","family":"Fu","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Nancy Chen","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maju","family":"Mathews","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"},{"name":"Perception Neuroscience, New York, NY, USA (current employment)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla M","family":"Canuso","sequence":"additional","affiliation":[{"name":"Janssen Research &amp; Development, LLC, Titusville, NJ, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,10,11]]},"reference":[{"key":"e_1_3_3_2_1","article-title":"Ketamine and other glutamate receptor modulators for depression in adults","volume":"9","author":"Caddy C","year":"2015","unstructured":"Caddy C, Amit BH, McCloud TL, et al. (2015) Ketamine and other glutamate receptor modulators for depression in adults. The Cochrane Database Syst Rev 9: CD011612.","journal-title":"The Cochrane Database Syst Rev"},{"key":"e_1_3_3_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001465"},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17060720"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3739"},{"key":"e_1_3_3_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2019.1189"},{"key":"e_1_3_3_7_1","article-title":"Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder","volume":"9","author":"Dean RL","year":"2021","unstructured":"Dean RL, Hurducas C, Hawton K, et al. (2021) Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder. The Cochrane Database Syst Rev 9: CD011612.","journal-title":"The Cochrane Database Syst Rev"},{"key":"e_1_3_3_8_1","first-page":"367","volume-title":"Essentials of Global Mental Health","author":"De Leo D","year":"2014","unstructured":"De Leo D, Too LS. (2014) Suicide and depression. In: Okpaku SO (ed.) Essentials of Global Mental Health. Cambridge: Cambridge University Press, pp. 367\u2013373."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725010-00003"},{"key":"e_1_3_3_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4050"},{"key":"e_1_3_3_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(03)00231-2"},{"key":"e_1_3_3_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyz039"},{"key":"e_1_3_3_13_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m13191"},{"key":"e_1_3_3_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60372-X"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyaa068"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/YCT.0b013e318283b7e9"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2015.15040465"},{"key":"e_1_3_3_18_1","first-page":"1","article-title":"Practice guideline for the assessment and treatment of patients with suicidal behaviors","volume":"160","author":"No Author","year":"2003","unstructured":"No Author (2003) Practice guideline for the assessment and treatment of patients with suicidal behaviors. Am J Psychiatry 160: 1\u201360.","journal-title":"Am J Psychiatry"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jagp.2019.10.008"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2019.19020172"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.6.1171"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2015.10.018"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.19m12891"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eurpsy.2011.06.003"},{"key":"e_1_3_3_25_1","volume-title":"The Global Burden of Disease: 2004 Update","author":"World Health Organization (WHO)","year":"2008","unstructured":"World Health Organization (WHO) (2008) The Global Burden of Disease: 2004 Update. Geneva: WHO."},{"key":"e_1_3_3_26_1","volume-title":"Sixty-Fifth World Health Assembly: Daily Notes on Proceedings","author":"World Health Organization (WHO)","year":"2012","unstructured":"World Health Organization (WHO) (2012) Sixty-Fifth World Health Assembly: Daily Notes on Proceedings. Geneva: World Health Organization."},{"key":"e_1_3_3_27_1","unstructured":"Zaki N Nash AI Chen N et al. (2021) Long-term safety and sustenance of response with esketamine nasal spray in patients with treatment-resistant depression: SUSTAIN-3 interim results. In: Psych Congress San Antonio TX USA 29 October\u20131 November 2021. Available at: https:\/\/www.eventscribe.net\/2021\/PsychCongress\/PosterTitles.asp?pfp=Title (accessed 6 September 2022)."}],"container-title":["Journal of Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221123046","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/02698811221123046","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/02698811221123046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:11:08Z","timestamp":1777507868000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/02698811221123046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,11]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1177\/02698811221123046"],"URL":"https:\/\/doi.org\/10.1177\/02698811221123046","relation":{},"ISSN":["0269-8811","1461-7285"],"issn-type":[{"value":"0269-8811","type":"print"},{"value":"1461-7285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,11]]}}}